Electra Therapeutics prices upsized $350m IPO on Nasdaq
Electra Therapeutics has priced an upsized initial public offering of 23,333,334 shares at $15.00 per share, raising gross proceeds of $350 million before underwriting costs. The South San Francisco company expects its shares to begin trading on the Nasdaq Global Select Market on 18 September 2026 under the ticker "ETRA", with closing anticipated on 21 September, subject to customary conditions.
The offering was upsized from its original size, indicating stronger-than-expected institutional demand. Underwriters led by Jefferies, TD Cowen, Evercore ISI and Cantor have been granted a 30-day option to purchase up to a further 3.5 million shares at the offering price, which if exercised in full would bring total gross proceeds to roughly $402.5 million.
The science behind the listing
Electra's pipeline centres on signal regulatory proteins (SIRPs), a family of cell-surface receptors whose expression is restricted to specific immune cell populations and rises upon activation. The company says its approach enables selective depletion of disease-driving cells while leaving normal immune function intact, a mechanism it describes as a novel class of precision medicines.
Its lead candidate, ipsoprubart (ELA026), is a pan-SIRP monoclonal antibody in a global registrational programme for secondary haemophagocytic lymphohistiocytosis (sHLH), a rare and severe hyperinflammatory syndrome. The company notes that no therapy has received broad regulatory approval for sHLH and that survival rates have not meaningfully improved over the past two decades, positioning ipsoprubart against a genuine unmet need. Ipsoprubart is also in a Phase 1 trial in relapsed or refractory T-cell and natural killer cell malignancies. A second asset, ELA822, is a SIRPγ-specific antibody aimed at chronic T cell-mediated immune and inflammatory diseases and has reached clinical stage.
Market context and competitive landscape
The SIRP pathway has attracted growing attention in immuno-oncology and autoimmunity research over the past several years. SIRPα is best known as the counter-receptor for CD47, a "don't eat me" signal on tumour cells, and a number of companies have pursued anti-CD47 or SIRPα-blocking strategies in oncology. Electra's pan-SIRP monoclonal antibody approach, and its application in hyperinflammatory disease rather than solid tumour oncology, represents a distinct positioning within this mechanistic space.
The sHLH indication is a high-risk, high-reward target. The condition carries significant mortality and has a small, clearly identifiable patient population, which may support an accelerated regulatory pathway; however, conducting registrational trials in critically ill patients presents operational challenges. Investors will watch closely for data readouts from the registrational programme and for any guidance on expected regulatory submission timelines, as these will be the principal catalysts determining whether the $15 offering price holds in the secondary market.
Broader conditions for biotech IPOs have been uneven in recent years, with listings clustering around windows of improved market sentiment. An upsized raise of this magnitude suggests Electra's underwriters saw sufficient appetite to absorb a larger book, though post-IPO performance will depend on clinical momentum rather than pricing dynamics alone.